Progenity Provides Corporate Updates and Reports Third Quarter 2020 Financial Results
November 09, 2020 16:05 ET
|
Progenity, Inc.
Reported 84 thousand tests in the third quarter, up 12% compared to the second quarter Achieved a preeclampsia test analytical verification milestone Management will host conference call and webcast...
Progenity Announces Encouraging Preclinical Data Supporting the Potential of the Company’s Oral Drug Delivery System in Targeting the Colon
November 06, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Report Third Quarter 2020 Financial Results and Provide Corporate Update
November 03, 2020 08:43 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces Successful Achievement of its Preeclampsia Test Analytical Verification Milestone
October 29, 2020 07:30 ET
|
Progenity, Inc.
Announces Expansion of its COVID-19 Testing Offering Provides Preliminary Third Quarter 2020 Financial Update SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a...
Progenity Presents Data from Award-Winning Abstract on Novel Ingestible Lab-in-a-Capsule at American College of Gastroenterology (ACG) 2020 Virtual Annual Meeting
October 27, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Present Precision Medicine Abstracts at American College of Gastroenterology (ACG) Virtual Annual Meeting in October
October 09, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Supports the Preeclampsia Foundation Call to Action to Accelerate Development and Adoption of Biomarker Tests for Preeclampsia
October 01, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces Addition to Russell 2000® Index
September 18, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Participate in Two Upcoming Investor Conferences
September 02, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Commends New Recommendations from ACOG and SMFM Supporting Non-Invasive Prenatal Testing (NIPT) for All Pregnancies
August 21, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...